創新醫療(002173.SZ):股東富浙資本再增持0.77%股份
格隆匯11月10日丨創新醫療(002173.SZ)公佈,公司於2020年11月10日收到股東富浙資本書面送達的《關於增持創新醫療管理股份有限公司股份的告知函》,富浙資本基於對公司未來持續發展的信心,於2020年10月29日-11月9日通過集中競價方式進一步增持公司股份348.1442萬股,佔公司總股本的0.77%。
截至2020年11月9日,富浙資本累計持有公司股份1828.5226萬股,佔公司總股本的4.02%。富浙資本及其一致行動人陳越孟、昌健投資、嵐創投資共同控制公司股份7346.3477萬股,佔公司總股本的16.15%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.